Full Text View
Tabular View
Study Results
Related Studies
A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation
This study has been completed.
Study NCT00723606   Information provided by Pfizer

First Received on July 25, 2008.   Last Updated on August 24, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Schizophrenia
Additional conditions recognized in this trial
Psychomotor Agitation
More general conditions related to this trial
Dyskinesias
Mental Disorders
Nervous System Diseases
Neurobehavioral Manifestations
Neurologic Manifestations
Psychomotor Disorders
Schizophrenia and Disorders with Psychotic Features
Signs and Symptoms
Interventions listed in this trial
Intramuscular ziprasidone mesylate
Intramuscular haloperidol
Additional drug interventions recognized in this trial
Haloperidol
Haloperidol decanoate
Ziprasidone
More general drug interventions related to this trial
Anti-Dyskinesia Agents
Antiemetics
Antipsychotic Agents
Autonomic Agents
Central Nervous System Agents
Central Nervous System Depressants
Dopamine Agents
Dopamine Antagonists
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Antagonists
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
Pfizer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services